American Society of Hematology

The American Society of Hematology (ASH) is a United States-based professional organization representing physicians, scientists, clinicians, and other specialists working in hematology and the study of blood, blood-forming organs, and blood disorders. Founded in 1958, the society developed during a period when hematology was becoming a more distinct scientific and clinical discipline. Its first official meeting took place in Atlantic City, New Jersey, in April 1958, where more than 300 hematologists gathered to discuss important research and clinical questions concerning blood diseases. ASH has since become a major professional platform for the hematology community. Its central activity is an annual meeting held each December. The four-day event combines educational programs, scientific sessions, plenary symposia, named lectures, and peer-reviewed oral and poster presentations. Abstracts submitted ahead of the meeting are evaluated by reviewers, allowing the program to showcase new findings in basic, translational, and clinical hematology. The meeting attracts tens of thousands of clinicians, researchers, and other participants from around the world, making it one of the most significant recurring gatherings in the field. The society also operates an extensive publishing and information portfolio. Its principal journal, Blood, is a peer-reviewed publication focused on hematology and is described in the reference material as the field's most cited journal. ASH additionally publishes Blood Advances, an online peer-reviewed open-access journal, as well as professional news and educational publications including ASH Clinical News and The Hematologist. Together, these publications support the dissemination of laboratory discoveries, clinical evidence, treatment developments, policy discussions, and professional updates. ASH's broader work includes professional education, scientific networking, patient and public policy advocacy, and support for the development of hematology as a specialty. The society reports more than 17,000 members, including professionals who have contributed to advances in the understanding and treatment of blood diseases. Its activities are supported in part through collaborations and financial relationships with pharmaceutical companies, including AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Sanofi, Takeda Pharmaceuticals, and Vertex Pharmaceuticals. These relationships coexist with ASH's role as a scientific and professional society, although the supplied material does not provide detailed information about governance safeguards or specific sponsored programs. ASH is best understood not as a consumer-facing commercial brand but as an international professional institution whose identity is built around scientific credibility, peer-reviewed knowledge, continuing education, and representation of the hematology community. Its principal offerings are events, journals, educational resources, and professional services rather than physical products. The society remains active, but specific current officers, headquarters details, membership figures by year, financial data, and recent strategic initiatives are not established by the supplied sources.

The American Society of Hematology was founded in 1958 as hematology was consolidating its identity as a specialized field linking laboratory science, clinical medicine, and the study of blood disorders. Its first official meeting was held in Atlantic City, New Jersey, in April of that year. More than 300 hematologists attended and discussed significant research and clinical issues related to blood and blood diseases. This initial gathering established the society's continuing practice of convening professionals to exchange scientific findings and address emerging clinical questions. Over the following decades, ASH supported the development of hematology by providing a recurring professional forum for researchers and clinicians. Its annual meeting, held in December, became the society's principal event. The meeting is organized as a multi-day program containing scientific sessions, educational activities, plenary symposia, named lectures, and oral and poster presentations. Research abstracts submitted before the event are selected through peer review, giving the meeting a formal mechanism for presenting new work across the field. The event's international attendance grew substantially, eventually reaching more than 21,000 clinicians, scientists, and other participants according to the supplied reference material. Publishing has been another central part of ASH's institutional history. The society publishes Blood, the Journal of the American Society of Hematology, a peer-reviewed journal focused on hematology research and clinical developments. The reference material identifies Blood as the most cited peer-reviewed publication in the field. ASH later added Blood Advances, an online, peer-reviewed open-access journal, broadening its channels for distributing hematology research. It also produces ASH Clinical News and The Hematologist, which provide professional news, commentary, educational material, and updates for members and the wider hematology community. In addition to meetings and publications, ASH functions as a membership and professional-development organization. It represents more than 17,000 members and supports education, networking, scientific communication, and advocacy related to blood diseases. The society's work connects basic research with clinical practice by bringing together investigators, physicians, and other specialists involved in understanding and treating hematologic conditions. ASH also maintains relationships with pharmaceutical companies that provide financial support or collaborate with the society. The named corporate partners in the supplied material include AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Sanofi, Takeda Pharmaceuticals, and Vertex Pharmaceuticals. The available material does not specify the terms, dates, or governance arrangements for these relationships. Today, ASH's institutional identity rests on its role as a professional society rather than a conventional commercial brand. Its principal public-facing assets are the annual meeting, journals, news publications, educational programs, and advocacy work. The supplied sources establish its founding, major activities, membership scale, and publication portfolio, but do not provide a complete chronology of later leadership, headquarters changes, financial performance, or individual strategic decisions.

• 1958

  Society founded and first official meeting held

  [1]American Society of Hematologyen.wikipedia.org

  ASH was founded, and its first official meeting took place in Atlantic City, New Jersey, in April. More than 300 hematologists attended to discuss research and clinical issues concerning blood diseases.

• Annual meeting established as a major hematology gathering

  [1]American Society of Hematologyen.wikipedia.org

  ASH's recurring December annual meeting developed into a large international forum featuring peer-reviewed research presentations, education, plenary symposia, and named lectures.

• Blood Advances added to ASH's publication portfolio

  [1]American Society of Hematologyen.wikipedia.org

  The society publishes Blood Advances as an online, peer-reviewed open-access journal alongside Blood.

A leading professional and scientific society for hematology, positioned around peer-reviewed research, clinical education, professional networking, and advocacy for the blood-disease community.

• Peer-reviewed medical journal

  Blood

  Blood is the Journal of the American Society of Hematology and a principal publication of the society. It publishes peer-reviewed research and clinical material concerning hematology, blood disorders, and related scientific developments. The supplied reference describes it as the most cited peer-reviewed publication in the field, making the journal a central part of ASH's scientific authority and knowledge-dissemination role.

• Open-access medical journal

  Blood Advances

  Blood Advances is ASH's online, peer-reviewed open-access journal. It extends the society's publishing activities by providing an additional venue for hematology research and related clinical or scientific material. Its digital and open-access format supports broader availability of published work than a conventional subscription-only journal.

• Professional conference · 1958

  ASH Annual Meeting

  The ASH Annual Meeting is a four-day event held each December. It includes educational programs, scientific sessions, plenary symposia, named lectures, and peer-reviewed oral and poster presentations selected from submitted abstracts. The meeting attracts more than 21,000 clinicians, scientists, and other participants and serves as the society's principal international forum for professional exchange.

• Professional publication

  ASH Clinical News

  ASH Clinical News is a professional publication associated with the society. It contributes news and information for the hematology community, complementing ASH's research journals and educational programming with material oriented toward clinical and professional developments.

• Professional publication

  The Hematologist

  The Hematologist is an ASH professional publication providing information and updates for people working in hematology. It forms part of the society's communications and education portfolio alongside its scientific journals, annual meeting, and other member resources.

1. 1American Society of Hematologyen.wikipedia.org
2. 2American Society of Hematology official websitehematology.org